Lisdexamfetamine dimesylate (vyvanse), a prodrug stimulant for attention-deficit/hyperactivity disorder

P and T

Volumn 35, Issue 5, 2010, Pages 273-287

  Goodman, David W ^a,b  

^a Johns Hopkins Green Spring   (United States)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHETAMINE; LISDEXAMFETAMINE; OMEPRAZOLE; PLACEBO;

ABDOMINAL PAIN; ANOREXIA; ANXIETY DISORDER; APPETITE; ATTENTION DEFICIT DISORDER; CLINICAL TRIAL; COUGHING; DIARRHEA; DRUG ABUSE; DRUG COST; DRUG DOSE COMPARISON; DRUG DOSE TITRATION; DRUG FATALITY; DRUG LABELING; DRUG MECHANISM; DRUG MEGADOSE; DRUG SOLUBILITY; DRUG WITHDRAWAL; FATIGUE; HEADACHE; HUMAN; INFLUENZA; INSOMNIA; IRRITABILITY; MORNING DOSAGE; NAUSEA; PSYCHOMOTOR ACTIVITY; REVIEW; RHINOPHARYNGITIS; SIDE EFFECT; SINGLE DRUG DOSE; SLEEP DISORDER; SUICIDAL IDEATION; UNSPECIFIED SIDE EFFECT; UPPER ABDOMINAL PAIN; UPPER RESPIRATORY TRACT INFECTION; VOMITING; WEIGHT REDUCTION; XEROSTOMIA;

EID: 77957172278     PISSN: 10521372     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (67)

1. Froehlich TE, Lanphear BP, Epstein JN, et al. Prevalence, recognition, and treatment of attention-deficit/hyperactivity disorder in a national sample of U.S. children. Arch Pediatr Adolesc Med 2007;161:857-864.
2. Faraone SV, Sergeant J, Gillberg C, Biederman J. The worldwide prevalence of ADHD: Is it an American condition? World Psychiatry 2003;2:104-113.
3. Weiss M, Hechtman LT, Weiss G. ADHD in Adulthood: A Guide to Current Theory, Diagnosis, and Treatment. Baltimore: Johns Hopkins University Press; 1999.
4. Kessler RC, Adler LA, Barkley R, et al. Patterns and predictors of attention-deficit/hyperactivity disorder persistence into adulthood: Results from the National Comorbidity Survey Replication. Biol Psychiatry 2005;57:1442-1451.
5. Barkley RA, Murphy KR, Fischer M. ADHD in Adults: What the Science Says. New York: Guilford Press; 2008.
6. Dulcan M, Work Group on Quality Issues. Practice parameters for the assessment and treatment of children, adolescents, and adults with attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry 1997;36(Suppl 10):85S-121S.
7. Kessler RC, Adler L, Barkley R, et al. The prevalence and correlates of adult ADHD in the United States: Results from the National Comorbidity Survey Replication. Am J Psychiatry 2006;163:716-723.
8. Fayyad J, de Graaf R, Kessler R, et al. Cross-national prevalence and correlates of adult attention-deficit hyperactivity disorder. Br J Psychiatry 2007;190:402-409.
9. Faraone SV, Biederman J, Spencer T, et al. Attention-deficit/ hyperactivity disorder in adults: An overview. Biol Psychiatry 2000;48:9-20.
10. Faraone SV, Perlis RH, Doyle AE, et al. Molecular genetics of attention-deficit/hyperactivity disorder. Biol Psychiatry 2005;57:1313-1323.
11. Shaw P, Eckstrand K, Sharp W, et al. Attention-deficit/hyperactivity disorder is characterized by a delay in cortical maturation. Proc Natl Acad Sci 2007;104:19649-19654.
12. Faraone SV. Etiology and pathophysiology of adult attention-deficit/ hyperactivity disorder. Prim Psychiatry 2004;11:28-40.
13. Kessler RC, Lane M, Stang PE, Van Brunt DL. The prevalence and workplace costs of adult attention deficit hyperactivity disorder in a large manufacturing firm. Psychol Med 2009;39:137-147.
14. Hinnenthal JA, Perwien AR, Sterling KL. A comparison of service use and costs among adults with ADHD and adults with other chronic diseases. Psychiatr Serv 2005;56:1593-1599.
15. Pliszka SR, Crismon ML, Hughes CW, et al. Texas Consensus Conference Panel on Pharmacotherapy of Childhood Attention-Deficit/Hyperactivity Disorder. The Texas Children's Medication Algorithm Project: Revision of the algorithm for pharmacotherapy of attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry 2006;45:642-657.
16. Pliszka S, AACAP (American Academy of Child and Adolescent Psychiatry) Work Group on Quality Issues. Practice parameter for the assessment and treatment of children and adolescents with attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry 2007;46:894-921.
17. The MTA Cooperative Group. A 14-month randomized clinical trial of treatment strategies for attention-deficit/hyperactivity disorder. Arch Gen Psychiatry 1999;56:1073-1086.
18. Molina BS, Hinshaw SP, Swanson JM, et al. the MTA Cooperative Group. MTA at 8 years: Prospective follow-up of children treated for combined-type ADHD in a multisite study. J Am Acad Child Adolesc Psychiatry 2009;48:484-500.
19. FDA. Minutes of the Drug Safety and Risk Management Advisory Committee, February 9, 2006. Available at: www.fda.gov/ ohrms/dockets/ac/06/minutes/2006- 4202M1-final-Minutes.pdf. Accessed September 28, 2009.
20. FDA. Minutes of the Pediatric Advisory Committee, March 22, 2006. Available at: www.fda.gov/ohrms/dockets/ac/06/minutes/2006-4210m- Minutes%20PAC%20March%2022%202006.pdf. Accessed September 28, 2009.
21. Swanson JM, Elliott GR, Greenhill LL, et al. Effects of stimulant medication on growth rates across 3 years in the MTA follow-up. J Am Acad Child Adolesc Psychiatry 2007;46:1015-1027.
22. Heal DJ, Cheetham SC, Smith SL. The neuropharmacology of ADHD drugs in vivo: Insights on efficacy and safety. Neuropharmacology 2009;57(7-8):608-618.
23. Greenhill LL, Abikoff HB, Arnold LE, et al. Medication treatment strategies in the MTA Study: Relevance to clinicians and researchers. J Am Acad Child Adolesc Psychiatry 1996;34:1304-1313.
24. Arnold LE, Christopher J, Huestis R, Smeltzer DJ. Methylphenidate vs. dextroamphetamine vs. caffeine in minimal brain dysfunction: Controlled comparison by placebo washout design with Bayes' analysis. Arch Gen Psychiatry 1978;35:463-473.
25. Focalin XR, package insert. East Hanover, N.J.: Novartis; March 2010.
26. Concerta, package insert. Titusville, N.J.: McNeil Pediatrics; November 2009.
27. Metadate CD, package insert. Smyrna, Ga.: UCB, Inc.; June 2009.
28. Ritalin LA, package insert. East Hanover, N.J.: Novartis; April 2009.
29. Adderall XR, package insert. Wayne, Pa: Shire US Inc.; March 2010.
30. Vyvanse, package insert. Wayne, Pa: Shire US Inc.; December 2009.
31. Albert A. Chemical aspects of selective toxicity. Nature 1958;182:421-423.
32. Krishnan S, Zhang Y. Relative bioavailability of lisdexamfetamine 70-mg capsules in fasted and fed healthy adult volunteers and in solution: A single-dose, crossover pharmacokinetic study. J Clin Pharmacol 2008;48(3):293-302.
33. Biederman J, Boellner SW, Childress A, et al. Lisdexamfetamine dimesylate and mixed amphetamine salts extended-release in children with ADHD: A double-blind, placebo-controlled, crossover analog classroom study. Biol Psychiatry 2007;62:970-976.
34. Ermer JC, Shojaei AH, Biederman J, Krishnan S. Improved interpatient pharmacokinetic variability of lisdexamfetamine dimesylate compared with mixed amphetamine salts extended release in children aged 6 to 12 years with attention-deficit/hyperactivity disorder. Poster presented at the American Psychiatric Association annual meeting, May 19-24, 2007, San Diego.
35. Ermer J, Homolka R, Martin P, et al. Lisdexam fetamine dimesylate: Linear dose proportionality, low inter- and intrasubject variability, and safety in an open-label single-dose pharmaco kinetic study in healthy adult volunteers. Poster presented at the American College of Clinical Pharmacy annual meeting, October 19-22, 2008, Louisville, Ky;
36. J Clin Pharmacol February 2010 (electronic version).
37. Shojaei A, Ermer JC, Krishnan S. Lisdexamfetamine dimesylate as a treatment for ADHD: Dosage formulation and pH effects. Poster presented at the American Psychiatric Association annual meeting, May 19-24, 2007, San Diego.
38. Haffey M, Buckwalter M, Zhang P, et al. Effects of omeprazole on the pharmacokinetic profiles of lisdexamfetamine dimesylate and extended-release mixed amphetamine salts in adults. Postgrad Med 2009;121:11-19.
39. Prilosec, package insert. Wilmington, DE: AstraZeneca; March 2010.
40. Pennick M. Absorption of lisdexamfetamine dimesylate and hydrolysis to form the active moiety, d-amphetamine. Poster presented at the annual meeting of the New Clinical Drug Evaluation Unit, June 29-July 2, 2009, Hollywood, Fla. (in press).
41. Pennick M. Hydrolytic conversion of lisdexamfetamine dimesylate to the active moiety, d-amphetamine. Poster presented at the Annual Scientific Convention and Meeting of the Society of Biological Psychiatry, May14-16, 2009, Vancouver;
42. Absorption of the prodrug lisdexamfetamine dimesylate and its subsequent enzymatic conversion to the active moiety d-amphetamine. Neuropsychiatric Dis Treat (in press).
43. Biederman J, Krishnan S, Zhang Y, et al. Efficacy and tolerability of lisdexamfetamine dimesylate (NRP-104) in children with attention-deficit/ hyperactivity disorder: A phase III, multicenter, randomized, double-blind, forced-dose, parallel-group study. Clin Ther 2007;29:450-463.
44. Wigal SB, Kollins SH, Childress AC, et al., 311 Study Group. A 13-hour laboratory school study of lisdexamfetamine dimesylate in school-aged children with attention-deficit/hyperactivity disorder. Child Adolesc Psychiatry Mental Health 2009;3:17-30.
45. Findling RL, Childress AC, Krishnan S, McGough JJ. Long-term effectiveness and safety of lisdexamfetamine dimesylate in school-aged children with attention-deficit/hyperactivity disorder. CNS Spectrums 2008;13:614-620.
46. Adler LA, Goodman DW, Kollins SH, et al., 303 Study Group. Double-blind, placebo-controlled study of the efficacy and safety of lisdexamfetamine dimesylate in adults with attention-deficit/hyperactivity disorder. J Clin Psychiatry 2008;69:1364-1373.
47. Wigal SB, Gupta S, Guinta D, Swanson JM. Reliability and validity of the SKAMP rating scale in a laboratory school setting. Psychopharmacol Bull 1998;34:47-53.
48. Swanson J, Wigal S, Greenhill L, et al. Objective and subjective measures of the pharmacodynamic effects of Adderall in the treatment of children with ADHD in a controlled laboratory classroom setting. Psychopharmacol Bull 1998;34:55-60.
49. Guy W, ed. ECDEU Assessment Manual for Psychopharmacology Revised. Rockville, Md: National Institute of Mental Health, U.S. Department of Health, Education, and Welfare, Pub. No. ADM 76-338. 1976, pp 218-222.
50. Lopez FA, Childress AC, Curtiss S. Improvement in attention-deficit/ hyperactivity disorder symptoms in children with lisdexamfetamine dimesylate versus extended-release mixed amphetamine salts and placebo in an analog classroom. Poster presented at the annual meeting of the American College of Clinical Pharmacy, October 19-22, 2008, Louisville, Ky.
51. Scheckner B, Schreckengost J, Favit A. Physician perception of clinical improvement with lisdexamfetamine dimesylate in children aged 6 to 12 years with attention-deficit/hyperactivity disorder. Poster presented at the annual meeting of the American Psychiatric Association, May 3-8, 2008, Washington, DC.
52. DuPaul GJ, Power TJ, Anastopoulos AD, Reid R. ADHD Rating Scale-IV: Checklists, Norms, and Clinical Interpretations. New York: Guilford Press; 1998.
53. Faries DE, Yalcin I, Harder D, Heiligenstein JH. Validation of the ADHD Rating Scale as a clinician-administered and scored instrument. J Atten Disord 2001;5:107-115.
54. Conners CK, Sitarenios G, Parker JDA, Epstein JN. The revised Conners' Parent Rating Scale (CPRS-R): Factor structure, reliability, and criterion validity. J Abnorm Child Psychol 1998;26:257-268. (Pubitemid 28359774)
55. Faraone SV, Biederman J, Spencer TJ, Aleardi M. Comparing the efficacy of medications for ADHD using meta-analysis. MedGenMed 2006;8:4.
56. Faraone SV, Schreckengost J. Lisdexamfetamine dimesylate effect size in children with attention-deficit/hyperactivity disorder. Poster presented at the American Academy of Child and Adolescent Psychiatry annual meeting, October 23-28, 2007, Boston.
57. Adler L, Weisler R, Goodman D, et al. Short-term effects of lisdexamfetamine dimesylate on cardiovascular parameters in a 4-week clinical trial in adults with attention-deficit/hyperactivity disorder. J Clin Psychiatry 2009;70(12):1652-1661.
58. Adler LA, Goodman D, Weisler R, et al. Effect of lisdexamfetamine dimesylate on sleep in adults with attention-deficit/hyperactivity disorder. Behav Brain Func 2009;5:34.
59. Brams M. Efficacy and safety of lisdexamfetamine dimesylate in adults with attention-deficit/hyperactivity disorder in the adult workplace environment. Presented at the annual meeting of the New Clinical Drug Evaluation Unit, June 29-July 2, 2009, Hollywood, Fla.
60. Weisler R, Young J, Mattingly G, et al. Long-term safety and efficacy of lisdexamfetamine dimesylate in adults with attention-deficit/hyperactivity disorder. Poster 206, presented at the U.S. Psychiatric and Mental Health Congress, October 30-November 2, 2008, San Diego.
61. Buysse DJ, Reynolds CF III, Monk TH, et al. The Pittsburgh Sleep Quality Index: A new instrument for psychiatric practice and research. Psychiatry Res 1989;28:193-213.
62. Mansbach RS, Moore RA Jr. Formulation considerations for the development of medications with abuse potential. Drug Alcohol Depend 2006;83S:S15-S22.
63. Jasinski DR, Krishnan S. Human pharmacology of intravenous lisdexamfetamine dimesylate: Abuse liability in adult stimulant abusers. J Psychopharmacol 2009;23:410-418.
64. Jasinski D, Krishnan S. Abuse liability and safety of oral lisdexamfetamine dimesylate in individuals with a history of stimulant abuse. J Psychopharmacol 2009;23:419-427.
65. Ermer J, Dennis K, Haffey M, et al. Pharmacokinetics of intranasal versus oral administration of lisdexamfetamine dimesylate in healthy adults. Poster presented at the American Psychiatric Association annual meeting, May 16-21, 2009, San Francisco.
66. Briesacher BA, Andrade SE, Fouayzi H, Chan KA. Comparison of drug adherence rates among patients with seven different medical conditions. Pharmacotherapy 2008;28:437-443.
67. Christensen LL, Sasané R, Hodgkins P, Harley CR. Treatment burden and costs of lisdexamfetamine dimesylate (LDX) users compared with users of other long-acting treatments in patients with attention-deficit hyperactivity disorder. Poster presented at the 14th Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research (ISPOR), May 16-20, 2009, Orlando.